Steering innovation in cancer therapeutics

AUM’s value driven drug development process for innovative cancer therapeutics, is a culmination of several decades of research in the treatment of Asia-prevalent cancers. With a singular goal of making cancer treatment accessible and affordable to all, AUM is led by a team of clinicians and medical researchers with global & diverse, clinical and commercial experience of 100+ years. Every stakeholder is passionate about what they do, with an emphasis on democratising cancer management and treatment.

VISHAL DOSHI, Chairman, Chief Executive Officer
  • Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD.
  • Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia
  • Key Opinion Leader to Korean Health Industry Development Institute
  • Previously held senior business development and management roles at IQVIA, EPS International and ICON
  • Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer
  • Bachelor of Pharmacy from University of Mumbai
Dr. HARISH DAVE, Co-Founder, Chief Medical Officer
  • Board-certified oncologist and hematologist with more than 35 years of experience
  • Conducted over 100 studies in hematology, oncology and transplantation
  • Extensive experience in managing regulatory authorities including successful submission of over 50 INDs
  • Structured and executed a private equity Novaquest–sponsored strategic virtual drug development collaboration between Quintiles and Eisai
  • Held various senior management positions at IQVIA, George Washington University Medical Center and VA Medical Center in Washington
TERIG HUGHES, Chief Financial Officer
  • Over 25 years of international experience in healthcare, scientific and medical publishing, information and analytics
  • Extensive financial management experience in growing businesses, with portfolios up to $400 million in annual turnover
  • M&A experience spanning Europe, USA and Asia and deals ranging from a $2 million JV formation with a leading Chinese University to integration of a $4.5 billion acquisition in the US
  • Previous senior leadership roles in Asia with Elsevier, as Finance Director for the Health Sciences Division, and Managing Director for India and South East Asia
Dr. JOHN PATAVA, Chief Operating Officer
  • 25 years of experience in medical research and clinical development of therapeutics products, including a 10-year period leading clinical operations at Bayer
  • Global Head of Scientific Affairs at Sirtex Technology Pty Ltd, an Australian listed oncology company, where he managed a global clinical operations budget in excess of A$20 million
  • Successfully delivered Sirtex’s global pivotal studies with a combined enrolment of 1103 patients, in over 200 investigator sites in 24 countries
  • Global Head of Biosimilar Development Business Group within Quintiles
  • Managed clinical trials in the indications of oncology, renal medicine, Chron’s disease, multiple sclerosis, hematology and surgery.
Dr. ZOU BIN, Chief Scientific Officer
  • Has developed multiple preclinical candidates among which NITD609 entered phase II clinical trials.
  • Co-inventor of a number of patents and has been featured in more than twenty publications in high impact journals, including Science and Nature
  • Previously worked at Shanghai Blueray Biopharma, Co., Ltd. as CEO and Co-founder, and was responsible for developing a strong pipeline of lymphoma/lung cancer drugs, taking the company’s value to more than 100 million RMB.
  • PhD and post-doctoral fellowship in synthetic chemistry with Prof. Dawei Ma (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences) and Prof. K. C. Nicolaou (Institute of Chemical and Engineering Sciences, A*STAR, Singapore).